<DOC>
	<DOCNO>NCT01752270</DOCNO>
	<brief_summary>Polycystic Ovary Syndrome common endocrine disorder woman , estimate affect 5 % population associate chronically elevate serum androgen concentrations.Evidence suggest polycystic ovary syndrome negative impact pregnancy outcomes , increase risk gestational diabetes , hypertensive disease pregnancy , preterm birth , partially related hyperandrogenic environment.Diane-35 prove effective anti-androgenic drug.At present , direct evidence Diane-35 positive effect clinical outcome polycystic ovary syndrome patient undergo In-vitro fertilization/Intracytoplasmic sperm injection .</brief_summary>
	<brief_title>Effect Diane-35 Pretreatment In-vitro Fertilization Outcome Patients With Polycystic Ovary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Cyproterone acetate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Cyproterone</mesh_term>
	<mesh_term>Cyproterone Acetate</mesh_term>
	<criteria>diagnose polycystic ovary syndrome patient accord Rotterdam criterion hyperandrogenism and/or clinical hyperandrogenic manifestation oral contraceptive treatment least 3 month experiment assist reproductive therapy accompany fallopian tube and/or male factor normal hepato/nephro function oral contraceptive pill contraindication , eg.Deep Venous Thrombosis smoking , drunk exclude infertile factor , eg.endometriosis , abnormal thyroid function , etc .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>